Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), OptimizeRx (OPRX) and AbbVie (ABBV)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Dexcom (DXCM – Research Report), OptimizeRx (OPRX – Research Report) and AbbVie (ABBV – Research Report).

Dexcom (DXCM)

In a report released today, Matt Miksic from Barclays maintained a Hold rating on Dexcom, with a price target of $138.00. The company’s shares closed last Friday at $124.34.

According to TipRanks.com, Miksic is a 5-star analyst with an average return of 6.6% and a 59.1% success rate. Miksic covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Zimmer Biomet Holdings, and Edwards Lifesciences.

Dexcom has an analyst consensus of Strong Buy, with a price target consensus of $154.13.

See today’s best-performing stocks on TipRanks >>

OptimizeRx (OPRX)

Barclays analyst Stephanie Davis maintained a Hold rating on OptimizeRx today and set a price target of $15.00. The company’s shares closed last Friday at $10.12.

According to TipRanks.com, Davis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -6.8% and a 40.0% success rate. Davis covers the Healthcare sector, focusing on stocks such as Walgreens Boots Alliance, Lifestance Health Group, and Quest Diagnostics.

OptimizeRx has an analyst consensus of Strong Buy, with a price target consensus of $16.17.

AbbVie (ABBV)

Barclays analyst Carter Gould maintained a Buy rating on AbbVie today and set a price target of $187.00. The company’s shares closed last Friday at $159.62.

According to TipRanks.com, Gould is a 4-star analyst with an average return of 7.8% and a 53.0% success rate. Gould covers the Healthcare sector, focusing on stocks such as Barinthus Biotherapeutics, Bristol-Myers Squibb, and Travere Therapeutics.

AbbVie has an analyst consensus of Strong Buy, with a price target consensus of $179.92, which is a 7.7% upside from current levels. In a report issued on April 22, Piper Sandler also maintained a Buy rating on the stock with a $185.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on DXCM:

• ABT, DHR, DXCM: Which “Strong Buy” Healthcare Stock Has More Upside?
• DexCom price target raised to $160 from $151 at Raymond James
• DexCom price target raised to $145 from $144 at Canaccord
• DexCom raises FY24 revenue view to $4.2B-$4.35B from $4.15B-$4.35B
• DexCom reports Q1 adjusted EPS 32c, consensus 27c